Results 81 to 90 of about 10,477 (203)

Comparison of efficacy of the tumour necrosis factor alpha blocking agents Etanercept and Infliximab in patients with active rheumatoid arthritis

, 2005
Background: Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved the outcomes in patients with rheumatoid arthritis (RA).
SANGARI D, DE FILIPPIS LG, MICALI G, ROMEO C, SCIBILIA G, BAGNATO, Gianfilippo, CALIRI A, LO GULLO R., BARTOLONE S   +8 more
core   +2 more sources

Etanercept-Induced Lupus Accompanied by Hemophagocytic Syndrome [PDF]

, 2011
Hemophagocytic syndrome (HPS) is a severe, potentially life-threatening disorder characterized by an excessive activation of macrophages, such as may occur in the setting of lupus.
Kawano, Mitsuhiro, Fujii, Hiroshi, Yamagishi, Masakazu, Araki, Daisuke, Yachie, Akihiro, Matsumura, Masami   +5 more
core   +2 more sources

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

Arthritis &Rheumatology, Accepted Article.
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G.W. Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard   +10 more
wiley   +1 more source

Effect of IT Etanercept on Adjuvant Arthritis

, 2013
Rats were immunized with CFA on day 0 and treated with IT etanercept (100 or 300 μg q.o.d.) beginning on day 1. (A) IT etanercept (Etan) significantly decreased paw swelling (*p = 0.001 for IT saline compared with either IT etanercept group) (
Camille I Svensson (65493), Toni L Jones (65491), Gary S Firestein (504), Deepa Hammaker (65492), Salvatore Albani (65494), Sanna Rosengren (2681), David L Boyle (2680), Linda Sorkin (65495)   +7 more
core   +1 more source

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic:results from the BSRBR-RA

, 2023
OBJECTIVES: Etanercept biosimilars show comparable efficacy to their originators among biologic-naïve patients with RA in RCTs. Nationwide guidelines have obligated prescribing of etanercept biosimilars from 2016 resulting in significant cost-savings ...
Tsoi, Man-Fung, Tsoi, Man Fung, Zhao, Sizheng Steven, Watson, Kath D, Kearsley-Fleet, Lianne; id_orcid, Kearsley-Fleet, Lianne, Hyrich, Kimme L, Watson, Kath, Lunt, Mark, Rokad, Aasiyah, Lunt, Mark; id_orcid, Hyrich, Kimme, Zhao, Sizheng; id_orcid   +12 more
core   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection

Frontiers in Immunology, 2017
Tumor necrosis factor-alpha (TNF-α) blockade is an effective treatment for rheumatoid arthritis (RA) and other inflammatory diseases, but in patients, it is associated with reduced resistance to the infectious agents Mycobacterium tuberculosis and ...
Nadia Belmellat, Nadia Belmellat, Luca Semerano, Luca Semerano, Luca Semerano, Noria Segueni, Diane Damotte, Patrice Decker, Patrice Decker, Bernhard Ryffel, Bernhard Ryffel, Valérie Quesniaux, Marie-Christophe Boissier, Marie-Christophe Boissier, Marie-Christophe Boissier, Eric Assier, Eric Assier   +16 more
doaj   +1 more source

Etanercept for the treatment of rheumatoid arthritis.

, 2003
BACKGROUND: Etanercept is a soluble tumour necrosis factor alpha-receptor DMARD for the treatment of rheumatoid arthritis (RA). OBJECTIVES: To assess the efficacy and safety of etanercept for the treatment of RA.
Barbara BTB Blumenauer, Amanda Burls, Wells, G, Ann Cranney, Cranney, A, George A Wells, Marc C Hochberg, Judd, M, Burls, Amanda, Blumenauer, B, Burls, A, Tugwell, P, Coyle, D, Peter Tugwell, Hochberg, M, Doug Coyle   +15 more
core   +1 more source

Etanercept In the treatment of AA-amyloidosis in juvenile rheumatoid arthritis

Научно-практическая ревматология, 2004
Objective. To study effect of etanercept, an antagonist of serum A amyloid production in the AA amyloidosis treatment in juvenile idiopathic arthritis (JIA). Material and methods.
H Mihels
doaj   +1 more source